Impact of Delaying the Addition of Anti-EGFR in First Line of
RAS Wild-Type Metastatic Colorectal Cancer: A
Propensity-Weighted Pooled Data Analysis

J 2022

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis

PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA et. al.

Basic information

Original name

Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis

Authors

PALMIERI, Lola-Jade, Tomas BUCHLER (203 Czech Republic), Antoine MEYER, Veronika VESKRNOVA (203 Czech Republic), Ondrej FIALA (203 Czech Republic), Petr BRABEC (203 Czech Republic, belonging to the institution), Jana BARANOVÁ (703 Slovakia, belonging to the institution) and Romain CORIAT (guarantor)

Edition

Cancers, BASEL, MDPI, 2022, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00128223

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers14061410

UT WoS

000776818400001

Keywords in English

metastatic colorectal cancer; RAS status; anti-EGFR; bevacizumab

Abstract

V originále

Simple Summary The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The introduction of anti-epidermal growth factor antibodies is commonly delayed because of late RAS testing results. Our objective was to evaluate the impact on the overall survival of delayed anti-EGFR introduction strategy. This study compared 305 patients with delayed anti-EGFR introductions, 401 with immediate anti-EGFRs, and 129 with immediate anti-VEGFs. The study suggests that delayed introduction has no deleterious impact on survival compared to the immediate introduction of an anti-EGFR or of an anti-VEGF. The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.

Citovat

PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA, Petr BRABEC, Jana BARANOVÁ and Romain CORIAT. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. Cancers. BASEL: MDPI, 2022, vol. 14, No 6, p. 1-10. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers14061410.

@article{2249114,
   author = {Palmieri, LolaandJade and Buchler, Tomas and Meyer, Antoine and Veskrnova, Veronika and Fiala, Ondrej and Brabec, Petr and Baranová, Jana and Coriat, Romain},
   article_location = {BASEL},
   article_number = {6},
   doi = {http://dx.doi.org/10.3390/cancers14061410},
   keywords = {metastatic colorectal cancer; RAS status; anti-EGFR; bevacizumab},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis},
   url = {https://www.mdpi.com/2072-6694/14/6/1410},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 2249114
AU  - Palmieri, Lola-Jade - Buchler, Tomas - Meyer, Antoine - Veskrnova, Veronika - Fiala, Ondrej - Brabec, Petr - Baranová, Jana - Coriat, Romain
PY  - 2022
TI  - Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
JF  - Cancers
VL  - 14
IS  - 6
SP  - 1-10
EP  - 1-10
PB  - MDPI
SN  - 20726694
KW  - metastatic colorectal cancer
KW  - RAS status
KW  - anti-EGFR
KW  - bevacizumab
UR  - https://www.mdpi.com/2072-6694/14/6/1410
N2  - Simple Summary The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The introduction of anti-epidermal growth factor antibodies is commonly delayed because of late RAS testing results. Our objective was to evaluate the impact on the overall survival of delayed anti-EGFR introduction strategy. This study compared 305 patients with delayed anti-EGFR introductions, 401 with immediate anti-EGFRs, and 129 with immediate anti-VEGFs. The study suggests that delayed introduction has no deleterious impact on survival compared to the immediate introduction of an anti-EGFR or of an anti-VEGF. The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.
ER  -

PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA, Petr BRABEC, Jana BARANOVÁ and Romain CORIAT. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. \textit{Cancers}. BASEL: MDPI, 2022, vol.~14, No~6, p.~1-10. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers14061410.

Detailed Information on Publication Record